false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Critica ...
Adjunctive Extracorporeal Therapies in Septic and ...
Adjunctive Extracorporeal Therapies in Septic and Inflammatory AKI
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Thiago Reis reviewed several adjunctive extracorporeal therapies for septic and inflammatory acute kidney injury (AKI). Polymyxin B hemoperfusion uses a cartridge to bind endotoxin; potential benefit appears linked to selecting patients with elevated endotoxin activity, though the evidence includes Bayesian trial analyses and requires careful interpretation. The selective cytopheretic device, approved for pediatric patients with sepsis-associated AKI on dialysis, aims to alter leukocyte activity.<br /><br />He also discussed styrene-divinylbenzene resin cartridges, which can adsorb inflammatory molecules but are nonselective and may remove important medications, including antibiotics and anticoagulants. Studies in cardiac surgery suggest possible biomarker or kidney benefits, but clinical evidence is mixed and some favorable findings come from retrospective analyses. An adsorptive dialysis filter has shown a reduction in mostly transient AKI in one trial, without clear improvement in major clinical outcomes. Finally, the Seraph cartridge is designed to capture pathogens, but current evidence remains limited.<br /><br />Reis emphasized that patient selection, medication monitoring, and cautious interpretation of early or surrogate-outcome studies are essential. In his own practice, the resin is used mainly to remove certain anticoagulants before urgent surgery or during bleeding, rather than for sepsis.
Asset Caption
Thiago Reis, MD, PhD
Meta Tag
Speaker
Thiago Reis
Keywords
acute kidney injury
sepsis
extracorporeal therapies
polymyxin B hemoperfusion
selective cytopheretic device
adsorptive dialysis filter
Seraph cartridge
×
Please select your language
1
English